23andMe Holding is engaged in developing direct-to-consumer precision medicine platform and a portfolio of genetically validated therapeutic candidates for various diseases across different therapeutic areas. Co.'s segments are: Consumer and Research Services, which provides its Personal Genome Service® telehealth business and research services; and Therapeutics, which focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies and consists of out-licensing of intellectual property associated with identified drug targets and activities related to therapeutic product candidates. The ME stock yearly return is shown above.
The yearly return on the ME stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ME annual return calculation with any dividends reinvested as applicable (on ex-dates).
|